Tirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It mimics these gut hormones to enhance insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety, leading to improved blood sugar control and significant weight loss. Approved by the FDA in 2022 for type 2 diabetes and 2023 for obesity, it's administered subcutaneously and is typically used alongside diet and exercise. Doses start at 2.5 mg and escalate to 5-15 mg based on tolerance.